Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617854 | 1.00 | AR (0.47) | ARMCHR1P2RY12AOC3IDE | |
| SCHEMBL2121399 | 1.00 | AR (0.47) | ARMCHR1P2RY12AOC3IDE | |
| SCHEMBL2119362 | 0.92 | AR (0.56) | ARPANK3 | |
| SCHEMBL2617855 | 0.92 | SMN1; SMN2 (0.48) | ARMCHR1IDESMN1; SMN2TRPV1 | |
| SCHEMBL2122662 | 0.92 | SMN1; SMN2 (0.48) | ARMCHR1IDESMN1; SMN2TRPV1 | |
| SCHEMBL2617784 | 0.92 | AR (0.56) | ARPANK3 | |
| SCHEMBL2617785 | 0.92 | SMN1; SMN2 (0.48) | ARMCHR1IDESMN1; SMN2TRPV1 | |
| SCHEMBL2617850 | 0.92 | AR (0.56) | ARPANK3 | |
| SCHEMBL2617819 | 0.91 | AR (0.43) | ARP2RY12AOC3TRPV1TRPA1 | |
| SCHEMBL2119055 | 0.91 | AR (0.43) | ARP2RY12AOC3TRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | AR 4346/4885MCHR1 2565/4885P2RY12 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.